Anuh Pharma Financial Statements

Anuh Pharma (ANUHPHARMA) reported revenue of ₹6.62B in FY2025 with net income of ₹473.52M. Total assets stood at ₹5.07B and free cash flow was ₹171.62M.

Anuh Pharma Income Statement

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Revenue		4.32B	4.87B	5.27B	6.47B	6.62B
Cost of Rev. Cost of Revenue		-3.30B	-3.78B	-4.01B	-4.87B	-4.99B
Gross Profit		1.02B	1.09B	1.26B	1.60B	1.62B
SGA Sales, General & Admin		-575.79M	-151.01M	-171.51M	-193.91M	-230.39M
Op. Income Operating Income		295.08M	348.86M	415.74M	665.66M	521.69M
PBT Profit Before Tax		385.51M	391.22M	474.70M	783.10M	610.05M
Net Income		284.36M	305.61M	361.80M	600.58M	473.52M
Dil. Shares Diluted Shares		100.22M	100.22M	100.22M	100.22M	100.22M
Diluted EPS		2.84	3.05	3.61	5.99	4.73

Figures in ₹ — millions (M), billions (B), trillions (T). EPS is earnings per share.

Understanding the Income Statement

The income statement shows Anuh Pharma's revenue and expenses over a period. Revenue minus costs gives gross profit; after operating expenses, interest, and taxes, the remainder is net income. Diluted EPS divides net income by all shares that could exist if options and convertibles were exercised.

Anuh Pharma Balance Sheet

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Curr. assets Total current assets		2.38B	2.59B	3.08B	3.39B	3.76B
Non-curr. assets Total non-current assets		949.09M	884.87M	973.68M	1.07B	1.30B
Total assets		3.33B	3.47B	4.05B	4.46B	5.07B
Curr. liabilities Total current liabilities		1.27B	1.31B	1.61B	1.53B	1.79B
Non-curr. liab. Total non-current liabilities		146.90M	24.96M	24.24M	17.68M	20.89M
Total liabilities		1.42B	1.33B	1.64B	1.54B	1.81B
Total equity		1.91B	2.14B	2.41B	2.91B	3.26B
Total liab. & eq. Total liabilities & equity		3.33B	3.47B	4.05B	4.46B	5.07B

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding the Balance Sheet

The balance sheet captures Anuh Pharma's financial position at a point in time — what it owns (assets), what it owes (liabilities), and the residual value to shareholders (equity). Total assets always equals total liabilities plus equity.

Anuh Pharma Cash Flow Statement

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Net Income		385.51M	391.22M	474.70M	783.10M	610.05M
Operating CF Cash flow Operating Activities		-187.35M	288.64M	539.02M	129.25M	371.25M
Capex Investments in PPE		-61.54M	-16.15M	-15.50M	-45.20M	-199.63M
Investing CF Cash flow Investing Activities		522.03M	-78.17M	-434.84M	9.18M	-199.09M
Dividend Paid		-215,000	-75.58M	-87.48M	-100.25M	-125.22M
Financing CF Cash flow Financing Activities		-331.15M	-194.49M	-122.87M	-85.68M	-48.60M
Cash (start) Cash at beginning of period		18.45M	21.98M	37.96M	19.27M	72.02M
Cash (end) Cash at end of period		21.98M	37.96M	19.27M	72.02M	195.57M
FCF Free Cash Flow		-248.89M	272.49M	523.52M	84.05M	171.62M

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding Cash Flow

The cash flow statement tracks how Anuh Pharma's cash moves through operations, investing, and financing activities. Free cash flow — operating cash minus capital expenditure — shows what is available to return to shareholders.

Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Mar-2025